Contera Pharma and BDD Pharma announce dosing of first subject in a Phase 1 trial of CP-012, a novel formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, and BDD Pharma, a drug delivery company specializing in modified and controlled release oral formulations, announce dosing of first subject in a Phase 1 pharmacoscintigraphic study in healthy volunteers. The study will evaluate a novel delayed-release, dual pulse levodopa / carbidopa tablet (CP-012), […]